Squamous cell carcinoma (SCC) of the head and neck is the most common malignancy of the upper aerodigestive tract.
Epidemiology
Prevalence – 34,000 new cases per year in the U.S.
Age – 50-60 years
Sex – males: females; 3:1
Ethnicity – African Americans more at risk than Caucasians
Risk Factors
Tobacco use – 5-25 fold higher risk
Alcohol use – if combined with smoking, geometrically increases risk
Occupational exposures
Exposure to nickel refining, chromium, mustard gas, radium
Woodworking and tanning byproducts
Viral infection
Epstein-Barr – associated with nasopharyngeal carcinoma
HPV 16/18/31 – most highly associated with carcinoma of lingual and palatine tonsils
Betel nut chewing
Pathology
The aerodigestive tract is lined with squamous cells
The majority of cancers arising in the aerodigestive tract are of squamous cell origin (90%)
Increased incidence over the past 10 years of the disease due to increased cancer of the base of the tongue and tonsils
Premalignant diseases (leukoplakia, erythroplakia, and dysplasia) can precede frank malignancy
SCC antigen
SCC antigen is expressed in normal epithelium and epithelial tissues
Neutral forms of SCC antigen normally remain inside the cell
Acidic SCC antigen is released and is often elevated in patients having SCC or other nonmalignant squamous cell lesions
Lipid associated sialic acid
Elevated concentrations of sialic acid are noted in inflammatory disorders and significant tissue necrosis
In cancer patients, elevated concentrations of sialic acid can be from the tumor cell surfaces as well as the nonspecific inflammatory responses associated with the malignancy
Malignant cells often exhibit aberrant sialylation, which has been implicated in the loss of contact inhibition and the metastatic potential of these cells
Clinical Presentation
Oral cavity – nonhealing ulcers of the floor of the mouth, tongue, buccal mucosa, hard palate; pain
Monitor patients with squamous cell carcinoma with serial determinations
Most useful for monitoring cancer recurrence following head and neck surgery for the removal of squamous cell carcinoma (recommend testing 4 weeks prior to surgery)
Elevated in patients with a variety of cancers
This test is not intended for use in diagnosing cancer
Results obtained with different assay methods or kits cannot be used interchangeably
Normally present in saliva, sweat, and respiratory secretions, so precautions must be taken to prevent sample contamination with these fluids
May be used as a sequential test for following tumor progression (Increasing SCC antigen concentrations are associated with tumor stage progression)
In cases where elevated or increased SCC antigen concentrations are observed, retesting of a new sample is indicated to exclude contamination
Use in conjunction with other tumor marker tests in managing select cancer patients (head and neck cancer, gynecological cancer, brain cancer, colorectal cancer and melanoma)
Use this test only in conjunction with other tumor marker tests
Lipid-associated sialic acid (LASA) has lower specificity and sensitivity than most tumor markers
May be modestly elevated in diabetes mellitus type 2
For fixed tissue samples, consultative services as well as immunohistochemical staining for EGFR, EGFR (H-11), EBV LMP, p53, NSE and ERA (moc-31) are available
General References
Agarwal V, Branstetter BF, Johnson JT.Indications for PET/CT in the Head and Neck.Otolaryngol Clin North Am. 2008;41(1):23-49. (Link to PubMed)
Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L.Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis.Head Neck. 2001;23(7):579-589. (Link to PubMed)
Ernster JA, Sciotto CG, O'brien MM, Finch JL, Robinson LJ, Willson T, Mathews M.Rising Incidence of Oropharyngeal Cancer and the Role of Oncogenic Human PapillomaVirus.Laryngoscope. 2007;-. (Link to PubMed)
Gillison ML.Current topics in the epidemiology of oral cavity and oropharyngeal cancers.Head Neck. 2007;29(8):779-792. (Link to PubMed)
Konkimalla VB, Suhas VL, Chandra NR, Gebhart E, Efferth T.Diagnosis and therapy of oral squamous cell carcinoma.Expert Rev Anticancer Ther. 2007;7(3):317-329. (Link to PubMed)
Lothaire P, de Azambuja E, Dequanter D, Lalami Y, Sotiriou C, Andry G, Castro G Jr, Awada A.Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation.Head Neck. 2006;28(3):256-269. (Link to PubMed)
Micke O, Bruns F, Schafer U, Horst E, Buntzel J, Willich N.The clinical value of squamous cell carcinoma antigen in patients irradiated for locally advanced cancer of the head and neck.Anticancer Res. 2003;23(2A):907-911. (Link to PubMed)
Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Vinolas N, Marquez A, Barreiro E, Borras J, Viladiu P.Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors.Tumour Biol. 2003;24(4):209-218. (Link to PubMed)
Ohno T, Nakayama Y, Nakamoto S, Kato S, Imai R, Nonaka T, Ishikawa H, Harashima K, Suzuki Y.Measurement of serum squamous cell carcinoma antigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix.Cancer. 2003;97(12):3114-3120. (Link to PubMed)
Quon H, Liu FF, Cummings BJ.Potential molecular prognostic markers in head and neck squamous cell carcinomas.Head Neck. 2001;23(2):147-159. (Link to PubMed)
van der Waal R, van der Waal I.Oral non-squamous malignant tumors; diagnosis and treatment.Med Oral Patol Oral Cir Bucal. 2007;12(7):E486-E491. (Link to PubMed)
Wycliffe ND, Grover RS, Kim PD, Simental A Jr.Hypopharyngeal cancer.Top Magn Reson Imaging. 2007;18(4):243-258. (Link to PubMed)
References from the ARUP Institute for Clinical and Experimental Pathology®
Layfield LJ.Fine-needle aspiration in the diagnosis of head and neck lesions: a review and discussion of problems in differential diagnosis.Diagn Cytopathol. 2007;35(12):798-805. (Link to PubMed)
Grenache, David G., Ph.D. Medical Director, Special Chemistry at ARUP Laboratories; Assistant Professor, Clinical Pathology, University of Utah
Layfield, Lester , M.D. Fine-Needle Aspiration Services and Molecular Diagnostics at ARUP Laboratories; Professor and Division Head, Anatomic Pathology, University of Utah
Perkins, Sherrie L. , M.D., Ph.D. Medical Director, Hematopathology at ARUP Laboratories; Professor, Anatomic Pathology, University of Utah
Comprehensive Review: May 2008
Last Update: May 2008